Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years.

被引：0
|
作者：
Wollenhaupt, J. [1 ]
Silverfield, J. [2 ]
Lee, E. B. [3 ]
Wood, S. P. [4 ]
Terry, K. [4 ]
Nakamura, H. [5 ]
Kwok, K. [6 ]
Anisfeld, A. [6 ]
Nduaka, C. [4 ]
Riese, R. [4 ]
Wang, L. [4 ]
机构：
[1] Univ Hamburg, Schoen Klin Hamburg Eilbek Teaching Hosp, Hamburg, Germany
[2] Healthpoint Med Grp, Tampa, FL USA
[3] Seoul Natl Univ, Seoul, South Korea
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, Tokyo, Japan
[6] Pfizer Inc, New York, NY USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
849
引用
收藏
页码：S375 / S375
页数：1
相关论文
共 50 条
  • [31] Tofacitinib, an oral JAK inhibitor, in the treatment of RA: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years
    DeMasi, R.
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Kwok, K.
    Lazariciu, I.
    Nduaka, C.
    Connell, C.
    Wang, L.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 20 - 20
  • [32] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: LONG-TERM EXTENSION STUDY OUTCOMES IN AN AUSTRALIAN RHEUMATOID ARTHRITIS POPULATION
    Hall, S.
    Nash, P.
    Rischmueller, M.
    Bossingham, D.
    Cook, N.
    Witcombe, D.
    Kwok, K.
    Thirunavukkarasu, K.
    [J]. INTERNAL MEDICINE JOURNAL, 2014, 44 : 26 - 26
  • [33] Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis: Interim data from OPAL Balance, an open label, long-term extension study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Kudlacz, Elizabeth
    Menon, Sujatha
    Kanik, Keith S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB224 - AB224
  • [34] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE SECOND INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S109 - S109
  • [35] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Fleishaker, Dona
    Wang, Cunshan
    Kudlacz, Elizabeth
    Menon, Sujatha
    Fallon, Lara
    Hendrikx, Thijs
    Kanik, Keith S.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [36] Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Fleishaker, Dona
    Wang, Cunshan
    Kudlacz, Elizabeth
    Menon, Sujatha
    Hendrikx, Thijs
    Kanik, Keith S.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [37] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Fallon, L.
    Hendrikx, T.
    Kanik, K. S.
    [J]. INTERNAL MEDICINE JOURNAL, 2018, 48 : 15 - 15
  • [38] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Fallon, L.
    Hendrikx, T.
    Kanik, K. S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1010 - 1011
  • [39] Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
    Fleischmann, Roy
    Yazici, Yusuf
    Wollenhaupt, Juergen
    Wang, Lisy
    Maniccia, Anna
    Kwok, Kenneth
    Takiya, Liza
    van Vollenhoven, Ronald
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [40] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Bloom, Stuart
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    [J]. GUT, 2018, 67 : A62 - A63
12345